News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ViaCell, Inc. (VIAC) Announces ViaCyte Collaboration with EMD Serono


9/4/2007 11:40:55 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ViaCell, Inc. (Nasdaq:VIAC) announced today it has entered into an agreement under which EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, will provide support related to the clinical development of ViaCyteSM, ViaCell’s investigational product for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. In addition, EMD Serono has agreed to provide certain quantities of two of its products, Gonal-f® RFF Pen (follitropin alfa injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection), for the treatment of patients participating in the ViaCyte study. Financial terms were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES